Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7316714 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1A | |
| SCHEMBL28369074 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1A | |
| Trifluoroacetic Acid SCHEMBL30392295 | 0.76 | BLM (0.55) | BLMESR1CA2CAMK2AESR2 | |
| SCHEMBL24253146 | 0.74 | BLM (0.62) | BLMESR1CA2CAMK2AESR2 | |
| SCHEMBL1906339 | 0.74 | BLM (0.62) | BLMESR1CA2CAMK2AESR2 | |
| SCHEMBL11226560 | 0.74 | BLM (0.62) | BLMESR1CA2CAMK2AESR2 | |
| SCHEMBL22074772 | 0.71 | BLM (0.59) | BLMESR1CA2CAMK2AESR2 | |
| SCHEMBL30887346 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1A | |
| SCHEMBL3736878 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1A | |
| SCHEMBL29112713 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1006 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153931-B1 | Forms of membrane transport vector penetratin; a membrane translocation peptide carrier moiety of given amino acid sequence; use in the improved delivery of therapeutic agents into target cells | CYCLACEL LIMITED (GB) | 2006-12-26 | — | — | US | claimed |
| US-7101967-B2 | Transport vectors | CYCLACEL LIMITED (GB) | 2006-09-05 | — | — | US | claimed |
| US-12637491-B2 | Antigenic peptides and uses thereof for diagnosing and treating autism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4742908-A1 | IMPROVED METHODS FOR GOS STABILIZATION IN YOGURT | International N&H Denmark ApS (DK) | 2026-05-20 | — | — | EP | disclosed |
| EP-4739330-A1 | CONSENSUS PEPTIDES IN HYA FOR USE IN TREATING DEGENERATED JOINTS | NuPep AS (NO) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739277-A1 | CONSENSUS PEPTIDES IN HYA | NuPep AS (NO) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739331-A1 | CONSENSUS PEPTIDES IN HYA FOR USE IN VISCOSUPPLEMENTATION | NuPep AS (NO) | 2026-05-13 | — | — | EP | disclosed |
| US-12624365-B2 | Method for modulating the alkaloid content of a tobacco plant | BRITISH AMERICAN TOBACCO (INVESTMENTS) LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727650-A1 | ANTI-FIBRIL ANTIBODIES | Immutrin Ltd (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260071225-A1 | BACTERIUM WITH REDUCED SENSITIVITY TO BACTERIOPHAGE | DUPONT NUTRITION BIOSCI APS (DK) | 2026-03-12 | — | — | US | disclosed |
| WO-1999054485-A1 | A METHOD FOR INHIBITING TUMOR INVASION OR SPREADING IN A SUBJECT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0938495-A1 | COMPOUNDS WHICH PREVENT NEURONAL CELL DEATH AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5929042-A | NEURONAL CELL CYTOPROTECTIVE OLIGONUCLEOTIDE FOR TREATING NEURODEGENERATIVE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-07-27 | — | — | US | disclosed |
| WO-1999018986-A1 | METHOD FOR INHIBITING THE BINDING OF LOW DENSITY LIPOPROTEIN TO BLOOD VESSEL MATRIX | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1999011283-A1 | METHOD FOR TREATING A SUBJECT SUFFERING FROM CONDITIONS ASSOCIATED WITH AN EXTRACELLULAR ZINC SPHINGOMYELINASE | THE TRUSTEES OF COLOMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1999007402-A1 | METHOD TO PREVENT ACCELERATED ATHEROSCLEROSIS USING (sRAGE) SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998038861-A1 | ANTISENSE COMPOUNDS WHICH PREVENT CELL DEATH AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998001145-A1 | THERAPEUTIC APPLICATIONS OF T-BAM (CD40L) TECHNOLOGY TO TREAT DISEASES INVOLVING SMOOTH MUSCLE CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997035876-A1 | COMPOUNDS WHICH PREVENT NEURONAL CELL DEATH AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637491-B2 | Antigenic peptides and uses thereof for diagnosing and treating autism | YBX1, ZP1, YBX3 | BLM 3983/4885ESR1 4748/4885CA2 1161/4885 |
| US-12624365-B2 | Method for modulating the alkaloid content of a tobacco plant | INMT, IPO5, IPO9 | BLM 2226/4885ESR1 4657/4885CA2 4730/4885 |
| US-20260071225-A1 | BACTERIUM WITH REDUCED SENSITIVITY TO BACTERIOPHAGE | O60361, UPF1, BPTF | BLM 953/4885ESR1 1898/4885CA2 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.